We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

In this article, we are going to look at where Regeneron ... shift in the Federal Reserve’s interest rate policies is a key driver of this upturn. Biotech is sensitive to changing rate patterns ...

Now, the company made a big shift to a more shareholder-centric approach by initiating their first-ever quarterly dividend of $0.88 per share in Q1 of this year. What is more, Regeneron has ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles ... Schleifer attributed the shift to more patients using off-label bevacizumab—aka Avastin—to treat their retinal ...